

JOIN US FOR A LUNCH SYMPOSIUM

# Overcoming the BBB using ultrasound

## FIRST IN HUMAN AND TRANSLATIONAL RESULTS

SEPTEMBER 17, 2022 - 13.00-14.00 - ROOM "FORUM" - PARTERRE LEVEL

**13.00 • 13.10** **Drug delivery challenges for glioblastoma**

**RICCARDO SOFFIETTI**  
MD, Science University Hospital,  
Torino, Italy

**13.10 • 13.20** **BBB Disruption Using Ultrasound:  
From concept to FIH**

**MICHAEL CANNEY**  
PhD, Carthera, Lyon, France

**13.20 • 13.40** **Clinical Review of SonoCloud-9 Studies  
for Glioblastoma and Intraoperative Drug  
Measurements**

**ADAM SONABEND**  
MD, Northwestern University,  
Chicago, IL, USA

**13.40 • 13.45** **Choice of Drugs and Perspectives**

**ROGER STUPP**  
MD, Northwestern Medicine,  
Chicago, IL, USA

**13.45 • 14.00** **Take home messages and Q&A**

**Moderators:**  
**ALEXANDRE CARPENTIER**  
MD, APHP, Paris, France  
**ROGER STUPP**  
MD, Northwestern University,  
Chicago, IL, USA

Over the past several decades, a wide variety of technologies have been explored to overcome the blood-brain barrier (BBB). Some of these have shown clinical benefit, but with technical limitations that have hampered their widespread adoption. The treatment of GBM is particularly affected by the inability of therapeutic compounds to reach infiltrated glioma cells at an effective concentration. BBB disruption using low-intensity pulsed ultrasound (LIPU) offers new hope in this field. SonoCloud, an implantable ultrasound device that overcomes the limitations of previous techniques, is currently being evaluated in clinical trials in Europe and the United States, with more than 450 treatments performed to date. An overview of nonclinical and clinical safety and efficacy data will be covered. This symposium will also be an opportunity to discuss new therapeutic perspectives opened by this technology.

**CARTHERA** 

